English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Hidradenitis suppurativa (HS) or acne inversa (AI) is a debilitating chronic inflammatory skin disease (1). Treatment of HS is challenging because of its persistence and poor response to treatment. Although only surgery leads to complete remission, antibiotics or biologics may be helpful. The potential efficacy of anti-tumor necrosis factor (anti-TNF) α agents to treat HS was demonstrated in a patient who received 5 mg/kg/day intravenous infliximab for Crohn’s disease (CD): HS lesions substantially improved after two doses (2). The use of anti-TNFα agents (infliximab and adalimumab) to treat HS has since been evaluated (3, 4). European guidelines were recently published (5).

Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option